Discovery of Pyrrolo[3,2- d ]pyrimidin-4-one Derivatives as a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor Bromodomain

作者：Luyi Huang, Hui Li, Linli Li, Lu Niu, Raina Seupel, Chengyong Wu, Wei Cheng, Chong Chen, Bi‐Sen Ding, Paul E. Brennan, Shengyong Yang · 发表于：Journal of Medicinal Chemistry · 年份：2019 · DOI：10.1021/acs.jmedchem.9b00096 · 被引用次数：19 · 研究领域：Protein Degradation and Inhibitors、Ubiquitin and proteasome pathways、Computational Drug Discovery Methods

Herein, we report the discovery of a series of new P300/CBP-associated factor (PCAF) bromodomain (BRD) inhibitors, which were obtained through a hit discovery process and subsequent structure-based optimization and structure–activity relationship analyses toward a retrieved hit compound ( 12 ). Among these inhibitors, ( R, R )- 36n is the most potent one with an IC 50 of 7 nM in homogeneous time-resolved fluorescence assay and a K D of 78 nM in isothermal titration calorimetry assay. This compound also exhibited activity against GCN5 and FALZ, but weak or no activity against other 29 BRD proteins and 422 kinases, indicating considerable selectivity. X-ray cocrystal structure analysis revealed the molecular interaction mode and the precise stereochemistry required for bioactivity. Cellular activity, preliminary RNA-seq analysis, and pharmacokinetic properties were also examined for this compound. Collectively, this study provides a versatile tool molecule to explore molecular mechanisms of PCAF BRD regulation and also offers a new lead compound for drug discovery targeting PCAF.